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INTRODUCTION
Lymphedema (LE) is a frequent complication of breast cancer treatment (i.e., surgery, radiation therapy (RT), chemotherapy (CTX)). LE is caused by a disruption in the lymphatic system that results in the accumulation of fluid in the interstitial space.
(1) LE manifests as swelling of the affected limb and is associated with chronic pain, disfigurement, reduced mobility, functional impairment, predisposition to infections, and increased health care costs.(2, 3)
The true incidence of breast cancer-related LE is unknown, though estimates range from 6% to 83%.(4) This wide variation is due to differences in diagnostic criteria, measurement techniques, timing of measurements, duration of follow-up, and sample characteristics. (5, 6) In a recent review of 11 prospective cohort studies,(7) the median incidence rate for LE within three years of breast cancer treatment was 20%. In the United States, this rate would mean that more than 500,000 breast cancer survivors are affected by this incurable condition. (8) Research is often directed at identifying risk factors for LE with the hope of developing interventions to reduce its incidence.(9) In our previous study,(13) we identified both phenotypic and genotypic differences between women who did and did not develop LE following breast cancer treatment.
The phenotypic characteristics associated with the occurrence of LE were increased BMI, increased number of lymph nodes removed, higher stage of disease, and having had a sentinel lymph node biopsy (SLNB). In addition, a number of candidate genes in the lymphatic and angiogenesis pathways were associated with LE (i.e., lymphocyte cytosolic protein 2 (LCP2), neuropilin-2 (NRP2), protein tyrosine kinase (SYK), Forkhead box protein C2 (FOXC2), vascular cell adhesion molecule 1 (VCAM1), and vascular endothelial growth factor -C (VEGFC)). While this study was novel in uncovering associations between LE and lymphatic and angiogenic candidate genes, further investigation is warranted to identify additional molecular pathways.
Several studies have suggested that cytokines may be involved in the pathophysiology of LE. (10, 11) Cytokines play a key role in modulating inflammatory responses, which may subsequently lead to lymphatic dysfunction and LE. (10) In a study that used a specific bioassay and performed transcriptional microarray analysis on human skin,(12) a number of cytokine genes (i.e., interleukin (IL) 4, IL6, IL10, 1 IL13) were up-regulated in LE specimens. In another study that investigated the role of inflammation in the regulation of fibrosis and lymphatic dysfunction,(11) the blockade of T-helper 2 cytokines, including IL-4 and IL-13, prevented T-cell differentiation and its subsequent inflammatory response in a mouse-tail model of LE. This blockade resulted in less fibrosis and improved lymphatic function. Findings from these studies suggest that variations in cytokine genes may account for the differences in the development of LE. Therefore, the purpose of this study was to determine if variations in pro-and anti-inflammatory cytokine genes were associated with the development of LE following breast cancer treatment.
METHODS a. Study Samples and Procedures
Demographic, clinical, and genomic data from a cross-sectional study (i.e., LE Study (NR0101282)) and a longitudinal study (i.e., Breast Symptoms Study (CA107091 and CA118658)) were combined for these analyses. Both studies used the same subjective and objective measures. Both studies were approved by the Committee on Human Research at the University of California, San Patients rated their functional status using the KPS scale that ranged from 30 (I feel severely disabled and need to be hospitalized) to 100 (I feel normal; I have no complaints or symptoms). Patients were asked to indicate if they exercised on a regular basis (yes/no). Clinical information was obtained from patient interviews and medical record reviews.
The Self-Administered Comorbidity Questionnaire (SCQ) is a short and easily understood instrument that was developed to measure comorbidity in clinical and health service research settings. (19) The questionnaire consists of 13 common medical conditions that were simplified into language that could be understood without any prior medical knowledge. Patients were asked to indicate if they had the condition using a "yes/no" format. If they indicated that they had a condition, they were asked if they received treatment for it (yes/no; proxy for disease severity) and did it limit their activities (yes/no; indication of functional limitations). Patients were given the option to add two additional conditions not listed on the instrument. For each condition, a patient can receive a maximum of 3 points.
Because there are 13 defined medical conditions and 2 optional conditions, the maximum score totals 45
points if the open-ended items are used and 39 points if only the closed-ended items are used. The SCQ has well-established validity and reliability and has been used in studies of patients with a variety of chronic conditions.(19-23)
c. Objective Measures
Bioimpedance Spectroscopy (BIS) of LE -BIS measurements, of the affected and unaffected arms, were done using the procedures described by Cornish and colleagues.(24-26) Patients were instructed not to exercise or take a sauna within 8 hours of the assessment. In addition, they were asked to refrain from drinking alcohol for 12 hours prior to the assessment. BIS measurements were taken using a single channel BIS device (i.e., SFB7 device; ImpediMed, San Diego, CA in the LE study or the Quantum X Bioelectrical Impedance Device; RJL Systems, Clinton Township, MI in the Breast Symptoms Study). Women removed all jewelry and their skin was prepped with an alcohol wipe prior to surface electrode placement. Patients lay supine on a massage table with their arms 30 degrees from the body and legs not touching for at least 10 minutes prior to the BIS measurements. Electrodes were placed on the dorsum of the wrists adjacent to the ulnar styloid process, the dorsum of the hands just proximal to the third metacarpophalangeal joint, anterior to the ankle joints between the malleoli, and over the dorsum of the feet over the third metatarsal bone just proximal to the third metatarsophalangeal joint. Two 'measurement' electrodes were placed at either end of the 40 cm length over which the circumference measurements were made and the 'drive' electrodes were placed 8 to 10 cm distal to these measurement electrodes. Two readings of resistance were obtained from the affected and unaffected arms and averaged for subsequent analyses.
While cases and non-cases of LE were known in the LE study, for the Breast Symptoms Study, LE cases were determined based on the procedures of Cornish and colleagues(24-26) using all of the data obtained from each woman during her participation in the study. A woman was defined as a LE case if the resistance ratio for the untreated arm/treated arm was >1.139 or >1.066 for those women who had surgery on the dominant or nondominant side, respectively at any of the BIS assessments.
d. Methods of Analysis for Phenotypic Data
Data were analyzed using SPSS Version 19.(27) Descriptive statistics and frequency distributions were generated on the sample characteristics. Independent sample t-tests, Chi-square analyses, and
Mann Whitney U tests were done to evaluate for differences in demographic and clinical characteristics between patients with and without LE. Blood collection and genotyping: Genomic DNA was extracted from archived buffy coats using the PUREGene DNA Isolation System (Invitrogen, Carlsbad, CA). Of the 543 patients recruited for this study, DNA was recovered from the archive buffy coat of 407 patients (i.e., 110 with and 297 without LE) who provided a blood sample. Genotyping was performed blinded to LE status and positive and negative controls were included. DNA was quantitated with a Nanodrop Spectrophotometer (ND-1000) and normalized to a concentration of 50 ng/μL (diluted in 10 mM Tris/1 mM EDTA). Samples were genotyped using the GoldenGate genotyping platform (Illumina, San Diego, CA) and processed according to the standard protocol using GenomeStudio (Illumina, San Diego, CA For SNPs that were members of the same haploblock, haplotype analyses were conducted in order to localize the association signal within each gene and to determine if haplotypes improved the strength of the association with the phenotype. Haplotypes were constructed using the program PHASE version 2.1. (32) In order to improve the stability of haplotype inference, the haplotype construction procedure was repeated five times using different seed numbers with each cycle. Only haplotypes that were inferred with probability estimates of >.85, across the five iterations, were retained for downstream analyses. Haplotypes were evaluated assuming a dosage model (i.e., analogous to the additive model).
Ancestry informative markers (AIMS) were used to minimize confounding due to population stratification. (33) (34) (35) Homogeneity in ancestry among patients was verified by principal component analysis, (36) using Helix Tree (Golden Helix, Bozeman, MT). Briefly, the number of principal components (PCs) was sought which distinguished the major racial/ethnic groups in the sample by visual inspection of scatter plots of orthogonal PCs (i.e., PC 1 versus PC2, PC2 versus PC3). This procedure was repeated until no discernible clustering of patients by their self-reported race/ethnicity was possible (data not shown). One hundred and six AIMs were included in the analysis. The first three PCs were selected to adjust for potential confounding due to population substructure (i.e., race/ethnicity) by including the three covariates in all regression models.
For association tests, three genetic models were assessed for each SNP: additive, dominant, and recessive. Barring trivial improvements (i.e., delta <10%), the genetic model that best fit the data, by maximizing the significance of the p-value, was selected for each SNP. Logistic regression analysis that controlled for significant covariates, as well as genomic estimates of and self-reported race/ethnicity, was used to evaluate the relationship between genotype and LE group membership. A backwards stepwise approach was used to create a parsimonious model. Genetic model fit and both unadjusted and covariate-adjusted odds ratios were estimated using STATA version 9. (37) As was done in our previous studies (15, 38, 39) , based on recommendations in the literature, (40, 41 ) the implementation of rigorous quality controls for genomic data, the non-independence of SNPs/haplotypes in LD, and the exploratory nature of the analyses, adjustments were not made for multiple testing. In addition, significant SNPs identified in the bivariate analyses were evaluated further using regression analyses that controlled for differences in phenotypic characteristics, potential confounding due to population stratification, and variation in other SNPs/haplotypes within the same gene. Only those SNPs that remained significant were included in the final presentation of the results.
Therefore, the significant independent associations reported are unlikely to be due solely to chance.
Unadjusted (bivariate) associations are reported for all SNPs passing quality control criteria in Table 1 to allow for subsequent comparisons and meta-analyses.
RESULTS

a. Differences in Demographic and Clinical Characteristics
As shown in Table 2 , no differences were found between patients with and without LE for the majority of the demographic and clinical characteristics. Patients with LE had a significantly higher body mass index (BMI) and a lower KPS score, and were more likely to report lung disease. In addition, patients with LE had a higher number of lymph nodes removed, a higher number of positive nodes, more advanced disease at the time of diagnosis, were less likely to have had a SLNB, were more likely to have had an axillary lymph node dissection (ALND), had received CTX prior to or following surgery, and had received RT following surgery.
b. Candidate Gene Analyses for the Development of LE
As summarized in 
c. Regression Analyses of IL4, IL10, and NFKB2 Genotypes and Haplotypes and the
Development of LE
In order to better estimate the magnitude (i.e., odds ratio, OR) and precision (95% confidence interval, CI) of genotype on the development of LE, multivariate logistic regression models were fit. As shown in Table 3 , in addition to genotype, the phenotypic characteristics included in the regression models were ethnicity (i.e., White, Black, Asian, Hispanic/Mixed ethnic background/Other), BMI, stage of disease, having a SLNB, and number of lymph nodes removed. Receipt of CTX and RT, while not significant after the inclusion of genomic estimates of and self-reported race/ethnicity, (13) were retained in all of the regression models for face validity.
The only genetic associations that remained significant in the multivariate logistic regression analyses were for IL4 rs2227284, IL10 rs1518111, IL10 rs1518110, and NFKB2 rs1056890 (see Table 3 and Figure 1 ). In the regression analysis for IL4 rs2227284, carrying two doses of the rare allele (i.e., CC+CA versus AA) was associated with a 69.9% decrease in the odds of developing LE ( Figure 1A ). In the regression analysis for IL10 rs1518111, carrying one or two doses of the rare allele (i.e., GG versus GA+AA) was associated with 51.0% decrease in the odds of developing LE ( Figure 1B ). The analyses for the second SNP in IL10, namely rs1518110, revealed that it is a perfect surrogate for IL10 rs1518111.
IL10 rs1518111 was selected to represent the two surrogate SNPs. In the regression analysis for NFKB2 rs1056890, carrying two doses of the rare allele (i.e., CC+CT versus TT) was associated with a 3.06-fold increase in the odds of developing LE ( Figure 1C ).
DISCUSSION
This study is the first to evaluate for variations in pro-and anti-inflammatory cytokine genes and the development of LE following breast cancer treatment. In brief, in the bivariate analyses (Table 2) , the phenotypic predictors of LE included: a higher BMI, lower KPS score, having lung disease, increased number of lymph nodes removed, increased number of positive lymph nodes, a higher stage of disease at the time of diagnosis, not having a SLND, having an ALND, and receiving CTX or RT. However, in the multivariate analysis (Table 3) , KPS score, having lung disease, number of positive nodes removed, and having an ALND were not retained in the final model (Table 3 ). In addition, when genomic estimates of and self-reported race/ethnicity were included in the multivariate logistic regression analysis,(13) neither receipt of CTX nor receipt of RT remained significant predictors of LE.
The complex molecular pathways that underlie the development of LE following breast cancer treatment are being uncovered. In our previous study,(13) variations in seven genes that play a role in lymphatic development and angiogenesis were associated with the development of LE. In this study, we extend this work and evaluated for variations in pro-and anti-inflammatory cytokine genes and their association with the development of LE.
Consistent with preclinical and clinical studies that identified a role for IL4 in the molecular pathway of LE development, (11, 12) patients who were homozygous for the rare allele in IL4 rs2227284
had a 69% decrease in the odds of developing LE. IL4 is a multifunctional cytokine that is known to In our study, patients who were heterozygous or homozygous for the rare allele in IL10 rs1518111 had a 51% decrease in the odds of developing LE. IL-10 rs1518111 is located in the intronic region of chromosome 1 in a region that undergoes DNA methylation. In addition, this SNP is known to influence active transcription factor binding sites (i.e., PU.1, Pol2). This SNP was associated with ischemic stroke,(46) benign prostate hyperplasia,(47) and Behcet's disease (i.e., a chronic vasculitis that affects the skin, joints, lungs, and central nervous system (48)). These studies suggest that variations in the expression of IL10 may result in increased inflammation and contribute to these diseases. In addition, in a sample of healthy controls who were homozygous for the rare allele in IL-10 rs1518111, mRNA expression and protein production of IL10 were decreased. (49) Recent evidence has implicated IL10 in the development of LE. (p52 and its precursor p100) is one of five subunits that contribute to dimeric NF-κB and is responsible for activating the non-canonical pathway of NF-κB.(52) NF-κB2 functions within an autoregulatory loop in which the precursor protein p100 is processed to become the active NF-κB2 subunit known as p52, which can up-regulate p100 expression. p100 can repress p52 activity, which acts as a negative feedback control loop. (53) This autoregulatory loop is tightly controlled.
In one study, Yang et al. (54) found that p52 transgenic mice that were deficient in the p100 precursor protein developed fatal lung inflammation characterized by diffuse alveolar damage with localized fibrosis. The lung tissue of the mice demonstrated high level induction of the Th1 cytokine IFN-γ and its inducible inflammatory chemokines, which are known to activate macrophages and result in a cycle of inflammatory processes and tissue damage. In addition, the transgenic mice displayed a significant increase in TNF-α which acts synergistically with IFN-γ to activate macrophages and regulate fibroblast proliferation and activation. NFKB2 rs1056890 is located near genes NF-κB PSD on chromosome 10 and is located in the 3' UTR region of NFKB2. In one study of Chinese patients with multiple myeloma patients, who were treated bortezomib,(51) individuals who were heterozygous or homozygous for the rare allele had an overall lower response rate and decreased survival. In relationship to LE, one can hypothesize that SNPs in the 3' UTR region of the NFKB2 gene may disrupt the engagement process needed for p100 proteolytic processing or affect its ability to repress p52 activity and disrupt the delicate autoregulatory loop.
Several limitations of this study need to be acknowledged. Although the sample size was relatively large, larger samples may reveal additional significant candidate gene associations. In addition, future studies need to confirm the functional effects of these polymorphisms.
CONCLUSION
Despite these limitations, the novel findings from this study suggest that genetic variations in proand anti-inflammatory cytokine genes may play a role in the development of secondary LE following breast cancer treatment. Although the pathophysiology of LE is complex and largely undetermined, the identified genetic associations may help with risk assessment and the development of targeted molecular therapy for this incurable condition. G>A n/a n/a n/a IL4 rs2243267 127206188 5 .217 G>C n/a n/a n/a IL4 rs2243274 127207134 5 .239 G>A n/a n/a n/a For each model, the first three principal components identified from the analysis of ancestry informative markers as well as self-report race/ethnicity (i.e., White, Black, Asian/Pacific Islander, Hispanic/Mixed ethnic background/Other) were retained in all models to adjust for potential confounding due to race or ethnicity (data not shown). Predictors evaluated in each model included genotype (IL4 rs2227284: CC + CA versus AA; IL10 rs1518111: GG versus GA + AA; NFKB2 rs1056890:
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